Speaker Profile
Ph.D., Professor, Hebrew U.
Biography
Professor Tabach leads the Deep Genomics Laboratory at the Hebrew University Medical School and is the founder of three companies specializing in genomics, cancer, and genetic diseases. He earned his PhD from the Weizmann Institute in systems biology and cancer, followed by postdoctoral training at Harvard Medical School in Professor Ruvkun’s lab, where he uncovered small-RN Ai pathways and mechanisms underlying genetic diseases by developing multi-omics methodologies. His research identifies novel drug targets that reveal cancer vulnerabilities by deciphering the exceptional responder phenomenon- rare stage-IV patients who experience remarkable tumor regression - enabling the selective elimination of cancer cells while minimizing harm to healthy tissue. Through both academic work and entrepreneurial initiatives, Professor Tabach develops innovative solutions for cancer, aging, and genetic diseases by translating animal “super-traits” into RNA-based therapies for humans. His functional genomics discoveries have revealed key disease pathways and cancer genes, significantly advancing drug discoveries and personalized treatment.
Talk
Turning Cancer’s Weapons Against Itself: GeneticBiomimicry Neo-Targets for EvolvingTherapy
Stage‑4 cancer patients face catastrophic outcomes: 95% mortality, less than 12‑month survival, and near‑universal treatment resistance. Our AI analysis of 200,000+ tumors maps 40 proprietary “genomic cracks” – cancer‑specific, irreversible changes that create unexpected chemical vulnerabilities – enabling dramatic improvement in GBM patients and optimized cocktails expected to impact ~100,000 patients/year worldwide.
AI and Data Sciences Showcase:
Hebrew University
Using AI analysis of tens of thousands of patients and massive multi‑omics data, ExceptionAIL is a precision oncology company that uncovers novel target types that efficiently exploit hidden tumor weaknesses, proposing a paradigm shift from chasing moving targets to attacking permanent vulnerabilities that tumors cannot repair.
Session Abstract – PMWC 2026 Silicon Valley
The PMWC 2026 AI Company Showcase will provide a 15-30 minute time slot for selected AI companies to present their latest technologies to an audience of leading investors, potential clients, and partners. We will hear from companies building technologies that expedite the pre-clinical and clinical drug discovery and development process, accelerate patient diagnosis and treatment, or develop scalable systems framework to make AI and deep/machine learning a reality.
